Bimzelx is a medicine used to treat the following inflammatory diseases: - moderate-to-severe plaque psoriasis (red, scaly patches on the skin) in adults who need systemic treatment (treatment with medicines affecting the whole body); - psoriatic arthritis (inflammation of the joints that often accompanies plaque psoriasis) in adults whose disease does not respond well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot take these medicines. For psoriatic arthritis, Bimzelx is used alone or with methotrexate; - axial spondyloarthritis (inflammation of the spine causing back pain) in adults whose disease does not respond well enough to conventional treatments. For this condition, it is used in patients who have signs of disease on X-rays (radiographic axial spondyloarthritis) as well as in patients who have clear signs of inflammation but no signs of disease on X-rays (non-radiographic axial spondyloarthritis); - hidradenitis suppurativa (acne inversa), a long-term skin disease that causes painful lumps, abscesses (collections of pus), fistulas (tunnels under the skin) and scarring on the skin. It is used in adults with moderate-to-severe active disease when conventional systemic treatments do not work well enough. Bimzelx contains the active substance bimekizumab.
Therapeutic Indication
### Therapeutic indication **Plaque psoriasis** Bimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. **Psoriatic arthritis** Bimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). **Axial spondyloarthritis** Non-radiographic axial spondyloarthritis (nr-axSpA) Bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs). Ankylosing spondylitis (AS, radiographic axial spondyloarthritis) Bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy. **Hidradenitis suppurativa (HS)** Bimzelx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.
Therapeutic Area (MeSH)
ATC Code
L04AC
ATC Item
白细胞介素抑制剂
Pharmacotherapeutic Group
bimekizumab
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| bimekizumab | N/A | Bimekizumab |
EMA Name
Bimzelx
Medicine Name
Bimzelx
Aliases
N/ANo risk management plan link.
